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Abstract: Glaucoma is a chronic disease requiring lifelong treatment. Discomfort due to 
medications may affect patients’ quality of life and may cause poor compliance, which leads 
to poor intraocular pressure control. To minimize the side effects of long-term treatment, 
preparations with lower benzalkonium chloride concentrations, preservative-free preparations 
and alternative preservatives have been developed and reported to have a lower rate of side 
effects. Tafluprost, launched on the ophthalmic market in 2008, is a new 16-phenoxy analogue 
of prostaglandin F2α, clinically used as an ocular hypotensive agent for the treatment of glaucoma 
and ocular hypertension. The safety and intraocular pressure-lowering efficacy of tafluprost has 
been demonstrated in various preclinical and clinical studies.
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Glaucoma is a group of diseases with a characteristic pattern of progressive optic 
neuropathy and a decrease in retinal sensitivity that cause visual loss. It is one of 
the most common causes of blindness worldwide. Due to aging of the population, 
the number of patients with glaucoma is expected to rise. It is a major public health 
problem and has economic consequences. Once the disease is diagnosed, treatment 
is required to stop progressive optic nerve damage. If glaucoma is not diagnosed and 
treated properly, it can lead to total and irreversible blindness.
The role of intraocular pressure (IOP) in glaucoma was suggested nearly 150 years 
ago and ocular hypotensive agents were used in treatment even before the exact 
mechanism by which they lowered IOP was understood. A large body of evidence 
has established the importance of IOP.1 Lowering IOP as much as possible improves 
the likelihood of delaying or halting the progression of optic nerve damage and visual 
field loss.2
Medical management is the first therapeutic approach to the treatment of glaucoma. 
Today, there is a large armamentarium of ocular hypotensive medications and 
physicians must consider various factors in determining the appropriate medication for 
patients. Efficacy, safety and tolerability, the mechanism of action for lowering IOP, 
compliance, and cost are important factors in drug treatment. The most commonly 
used criteria for evaluating efficacy is IOP decrease in the treated subjects. Control of 
IOP over a 24-hour period is also important; IOP must stay fairly constant. The side 
effects of medications must be evaluated for each patient prior to treatment. In terms 
of compliance, patients comply more easily with treatment regimens if they instill 
eye drops less frequently.3
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Prostaglandin derivatives and prostamides, which are 
a relatively new class of ocular hypotensive agents, are 
very effective in lowering IOP. They are biologically 
active derivatives of arachidonic acid. Arachidonic acid 
is later converted to prostaglandins, which are normally 
present in ocular tissues and mediate or modulate a broad 
spectrum of biological processes. Prostaglandin analogues 
are a very effective and useful class of drugs in the treat-
ment of glaucoma. They reduce IOP by increasing uveo-
scleral outflow and to some degree, conventional outflow. 
Latanoprost, bimatoprost, and travoprost are used once daily 
and unoprostone is used twice daily. Because very low con-
centrations are used in glaucoma treatment and the plasma 
half-life is short, systemic side effects are rare. Conjunctival 
hyperemia, stinging, burning, eyelash changes, increased 
iris pigmentation, cystoid macular edema in aphakic and 
pseudophakic eyes, reactivation of herpes keratitis, and 
anterior uveitis are local side effects.4
Latanoprost is an analogue of prostaglandin F2α. It 
reduces IOP very effectively with minimal systemic side 
effects. Although the underlying mechanism remains 
unclear, latanoprost lowers IOP by increasing uveoscleral 
outflow. It was hypothesized that prostaglandins may stimu-
late collagenase and other metalloproteinases to degrade 
the extracellular matrix between ciliary muscle bundles.5 
Studies have reported a 20%–40% decrease in IOP after 
latanoprost treatment. Ocular hypertension and primary 
open-angle glaucoma (POAG) patients had a high chance 
of experiencing a sufficient IOP reduction with latanoprost 
monotherapy during 2 years of treatment.6 This drug has 
been effective in several glaucoma subtypes. It is used in 
a 0.005% concentration. Bimatoprost has been described 
as a prostamide. It was reported not to be a prostaglandin 
and does not act on prostanoid receptors. However, binding 
of bimatoprost to the FP prostanoid receptor, which is the 
same receptor selectively activated by latanoprost, has been 
demonstrated. Bimatoprost was shown to be as effective 
as latanoprost with a higher percentage of conjunctival 
hyperemia.7 It is used in a 0.03% concentration. Travoprost 
is a topical ocular ester prodrug that is rapidly hydrolyzed 
to biologically active free acid structurally similar to other 
prostaglandin F2α analogues. The IOP-lowering effect of 
travoprost is comparable to latanoprost.8 Travoprost is com-
mercially available in a 0.004% concentration. Unoprostone 
isopropyl is another prostaglandin F2α analogue that was first 
introduced in Japan. It is administered twice daily in a 0.15% 
concentration and has been found to be less effective than 
other drugs of this class.9
Tafluprost (1-methylethyl [5Z]-7-[(1R,2R,3R,5S)-2-[(1E)-
3,3-difluoro-4-phenoxy-1-butenyl]-3,5-dihydroxycyclo-
pentyl]-5-heptenoate) is a unique 16-phenoxy analogue of 
prostaglandin F2α with a 15,15-difluoro substitution, which 
is clinically used as an ocular hypotensive agent to treat glau-
coma and ocular hypertension patients.10,11 It was launched 
on the ophthalmic market in 2008. It is used in a 0.0015% 
concentration in single-use containers, dosed once daily in 
the evening. Tafluprost is an isopropyl ester prodrug that is 
rapidly hydrolyzed by corneal esterases to the free acid of 
tafluprost (the active form). In this way, it facilitates corneal 
penetration. The metabolite of tafluprost, tafluprost acid, has 
an increased affinity for the prostanoid FP receptor compared 
to latanoprost.10
Topical antiglaucomatous agents are associated with 
various adverse effects, such as burning, a stinging sensation, 
tearing, dry eye, and allergic reactions. Discomfort due to 
medications may affect patients’ quality of life and may 
cause poor compliance. Poor compliance leads to poor IOP 
control. Glaucoma is a chronic disease requiring lifelong 
treatment; therefore, to minimize the side effects of long-term 
treatment, preparations with lower benzalkonium chloride 
(BAC) concentrations, preservative-free preparations, and 
alternative preservatives have been developed and have been 
shown to have a lower rate of side effects.12
There is a growing body of evidence demonstrating that 
some local adverse effects may be the result of preservatives 
rather than active compounds. BAC is a cationic detergent and 
the most commonly used preservative in topical ophthalmic 
preparations. It ranges in concentration from 0.02%–0.004% 
and is used in approximately three quarters of all eye drops. 
BAC interacts with membrane proteins and may change the 
ionic resistance of the cornea by intercalating into the cellular 
membrane.13 It can accumulate in ocular tissues for long peri-
ods and may induce cell toxicity in a dose-dependent manner. 
The detergent effect of BAC may cause loss of tear film stability, 
toxicity of the corneal and conjunctival epithelium, and immu-
noallergic reactions.13,14 Corneal cell dysfunction and lysis were 
found to be related to the concentration and duration of expo-
sure.13 In vivo application of 0.005% BAC solution in rabbits 
caused swelling and desquamating of superficial corneal epi-
thelial cells, demonstrated by scanning confocal microscopy.15   
It was found that conjunctival cells die by necrosis at high 
concentrations of BAC and by apoptosis at low concentrations 
of BAC.16 Other ophthalmic preservatives are thiomersal, 
benzododecinium bromide, cetrimide, EDTA, p  henylmercuric 
nitrate, chlorobutanol, PHBG, sodium perborate, sorbic 
acid, clorhexidine digluconate, and parahydroxybenzoat.14,17 
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Purite, PQ-1, and SofZia are other ophthalmic preservatives 
designed  to  eliminate  the  toxic  adverse  effects  of 
preservatives.
An ex vivo and in vitro study has demonstrated that 
preserved formulations of latanaprost and timolol induced 
higher proinflammatory, proapoptotic, and toxic effects on 
conjunctival cells than a nonpreserved timolol preparation.18 
Other adverse effects of BAC include significant instability 
of precorneal tear film, toxicity to the trabecular meshwork, 
and an increased rate of failed glaucoma surgery.19–21 
Reduction in corneal cell proliferation and viability causing 
epithelial barrier problems, a significant degree of squamous 
metaplasia, inflammation, and subconjunctival fibrosis have 
been observed with preservatives even though some of 
these effects are still being debated.19,22–24 There is general 
acceptance that a change from preserved to nonpreserved 
preparations was associated with a significant decrease of 
the signs and symptoms of ocular irritation. Even though 
BAC was shown to increase the corneal permeability of 
pharmacological agents,25 controversial data exists that   
BAC and BAC-free formulations have similar efficacy.26 
BAC was demonstrated to act as an absorption enhancer to 
improve drug penetration through cellular membranes in the 
cornea. The absorption of acyclovir increased tenfold with 
0.01% BAC.25 However, in a study comparing nonpreserved 
and preserved 0.1% T-Gel eye gel, the preservative did not 
have an effect on the IOP-lowering efficacy.27 BAC-free 
travoprost 0.004%, formulated with the SofZia system, 
(Travatan Z®; Alcon, Hünenberg, Switzerland) was com-
pared to BAC-preserved marketed formulation travoprost 
0.004% (Travatan, Alcon) and was found equivalent in 
terms of safety and efficacy.26 Single-dose unit preservative-
free glaucoma medications such as timolol gel 0.1% and a 
timolol and dorzolamide combination have been introduced 
on the ophthalmic market.27 Even though single-dose unit 
eye drops remained free of bacterial contamination for up to 
1 day after opening, their cost and difficulty of use for older 
patients are major disadvantages.17,27 Corneal penetration of 
preserved and nonpreserved formulations of topical tafluprost 
applications in rabbit eyes were compared.28 The penetra-
tion of topically applied nonpreserved tafluprost 0.0015% 
eye drops into the aqueous humor of rabbits was similar to 
the penetration of tafluprost 0.0015% eye drops preserved 
with 0.01% BAC. BAC did not have an effect on the corneal 
penetration of tafluprost into the aqueous humor.28
Prostaglandin F2α has been known to have antiapoptotic 
effects in some cell types and tissues.29 Tafluprost promoted 
survival and inhibited apoptotic events in serum-deprived and 
glutamate-exposed retina ganglion cells in an experimental 
study where cultured retina ganglion cells and rat retina 
ganglion cells with optic nerve crash were used.30 Tafluprost 
reduced Ca in rat retina ganglion cells exposed to glutamate. 
In glaucoma, excessive amounts of glutamate are considered 
to be an important factor causing apoptosis in retina ganglion 
cells. In vivo prostanoid agonists have been found to protect 
retina ganglion cells from injury,30–32 perhaps by suppressing 
apoptosis through the inhibition of caspase-3 activation.33 
In one study, the application of tafluprost to retinal explants 
enhanced retina ganglion cell survival significantly, suggest-
ing a direct neuroprotective ability concomitant with ocular 
hypotensive effects.34
The tissue distribution and metabolism of tafluprost was 
evaluated in cynomolgus monkeys.35 After a single dose of 
an ophthalmic solution containing 0.0005%, 0.005%, or 
0.05% tafluprost was topically instilled (20 mL/eye), blood, 
ocular and systemic tissues, or excreta were collected for 
24 hours after the drug instillations. High concentrations 
of drug-related radioactivity were observed in the cornea 
and conjunctiva, followed by the iris, sclera, choroid with 
retina pigment epithelium, and aqueous humor. The high-
est concentration of radioactivity occurred in ocular tissues 
within 2 hours after dosing. The measured radioactivity in the 
tissues was proportional to the administered dose. The major 
tafluprost metabolites in the ocular tissues were tafluprost 
acid, 1,2-dinor- and 1,2,3,4-tetaranor-tafluprost acid. The 
concentration of tafluprost acid in the aqueous humor and 
ciliary body was enough to stimulate prostanoid FP receptors. 
The major metabolites were intracamerally injected in order 
to observe their antiglaucomatous effects. Tafluprost acid was 
shown to significantly lower the IOP, while 1,2-dinor- and 
1,2,3,4-tetaranor-tafluprost acid did not.35 Tafluprost was 
well absorbed to ocular tissues. The major metabolite and 
only active form of tafluprost acid was further metabolized 
by β oxidation to inactive metabolites. Even though there are 
no other pathways for metabolic inactivation, tafluprost did 
not accumulate in tissues.36 After both single and multiple 
topical applications, the plasma concentration of tafluprost 
remained at low levels. The peak plasma concentration was 
reached at 10 minutes, and it was detected in plasma for up 
to 1 hour after topical application.37
The ocular hypotensive efficacy of tafluprost has 
been demonstrated in various preclinical animal studies. 
Single-dose applications of tafluprost have demonstrated 
IOP-lowering efficacy in both ocular normotensive and 
laser-induced ocular hypertensive monkeys. A statistically 
significant IOP reduction was achieved after a single dose 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
675
Pharmacology and utility of tafluprostClinical Ophthalmology 2012:6
of 0.0005% and 0.0025% tafluprost when compared to a 
vehicle. An IOP-lowering efficacy of 0.0025% tafluprost 
was greater than 0.005% latanoprost and 0.0005% tafluprost 
was almost equal to 0.005% latanoprost.10 Kurashima et al 
switched monkeys which had a low susceptibility and an 
inadequate IOP reduction by latanoprost treatment to taflu-
prost treatment. It was demonstrated that the IOP reduction 
induced by tafluprost 0.0015% (2.4 mmHg) was significantly 
greater than latanoprost 0.005% (0.4 mmHg) in all monkeys 
tested. This effect disappeared after switching back to latano-
prost. Latanoprost low responders exist among monkeys 
and these results suggested that tafluprost may be effective 
for latanoprost nonresponder patients.38 The IOP-lowering 
effect and mechanism of action was studied in prostanoid 
receptor-deficient mice. It was concluded that tafluprost 
lowers IOP through the prostanoid FP receptor. Part of the 
ocular hypotensive effect of tafluprost was attributed to FP 
receptor-mediated prostaglandin production acting through 
the prostanoid EP3 receptor.39
The pharmacodynamics, safety, and tolerability of 
tafluprost were evaluated in various clinical studies. The 
efficacy, safety, and tolerability of tafluprost 0.0015% 
were compared to the efficacy, safety, and tolerability of 
latanoprost 0.005% in patients with POAG, exfoliation 
glaucoma, or ocular hypertension in a randomized, double-
masked, active-controlled, parallel-group, multinational 
and multicenter phase II study. Maximum IOP reduction 
was achieved by day 7 and was sustained in both groups. 
Tafluprost and latanoprost had comparable effects on the 
extent, duration, and stability of IOP reduction, and were 
well tolerated in patients.40 The long-term efficacy and 
safety of tafluprost 0.0015% were compared to long-term 
efficacy and safety of latanoprost 0.005% eye drops in 
patients with POAG or ocular hypertension in a double-
masked, active-controlled, parallel-group, multinational, 
multicenter, phase III study conducted at 49 centers in eight 
countries. Both treatments had a substantial IOP-lowering 
effect that persisted throughout the study (-7.1 mmHg for 
tafluprost and -7.7 mmHg for latanoprost at 24 months). 
Although the IOP-lowering effect was slightly greater with 
latanoprost, the difference was clinically small and the non-
inferiority of tafluprost to latanoprost over all diurnal IOP 
measurements was shown. Both drugs were well tolerated 
and adverse events were mild to moderate. The most fre-
quently reported adverse effect was conjunctival hyperemia. 
The stimulating effect on eyelash growth was absent or mild 
in 90% of patients in both groups after 24 months. More 
cases of iris pigmentation were reported in the latanoprost 
group (28%) than in that treated with tafluprost (26.1%), but 
the differences were not significant.41 The pharmacokinetics 
and efficacy of preserved and preservative-free tafluprost 
0.0015% were evaluated in a randomized, investigator-
masked, multicenter, crossover phase III study. The drugs 
were administered for 4 weeks in 43 patients with POAG 
or ocular hypertension. After 4 weeks, no significant dif-
ference in pharmacokinetic parameters between the for-
mulations after single or repeated dosing was observed. 
Ocular hyperemia occurred with the same frequency in 
both groups, but was predominantly of moderate sever-
ity in eyes treated with preserved tafluprost, compared to 
only mild severity with the preservative-free formulation.37 
In another study, the diurnal IOP-lowering efficacy and 
safety of travoprost 0.004% and tafluprost 0.0015% was 
compared. The drugs were administered to patients with 
POAG or ocular hypertension in a randomized, double-
masked, active-controlled, crossover design trial for six 
weeks and then the alternative treatment was administered 
for a subsequent six weeks. The 12-hour mean diurnal IOP 
was significantly lower with travoprost than with taflu-
prost (16.9 mmHg versus 17.5 mmHg). Neither treatment 
produced a significant increase from baseline in light 
sensitivity, blurred-dim vision, stinging/burning, foreign 
body sensation, or pain. Hyperemia was increased with 
both therapies. Investigator-observed hyperemia was also 
significantly increased from baseline for both travoprost 
and tafluprost. The increase with travoprost treatment was 
significantly smaller than with tafluprost.42
Abnormal vascular regulation has been suggested to be 
involved in the development of POAG. Studies have shown 
decreased optic nerve head (ONH) and retinal blood flow 
in patients with POAG. The short-term effect of topical 
tafluprost on feline retinal circulation was investigated using 
a laser Doppler velocimetry system. Tafluprost 0.0015% 
significantly increased retinal blood flow and blood velocity 
for 120 minutes after instillation, while there was no sig-
nificant change in vessel diameter.43 Akaishi compared the 
effects of repeated administrations of three prostaglandin 
F2α analogs (tafluprost, latanoprost, and travoprost) on ONH 
blood flow in normal rabbits using laser speckle flowgraphy. 
They found that ONH blood flow increased after 28 days of 
treatment with any of the three agents. The effect of tafluprost 
was significantly greater than that seen with travoprost and 
tended to be greater than that seen with latanoprost.44 Another 
study investigated the effects of topically administered taflu-
prost 0.0015%, 15-hydroxyl tafluprost (15-OH tafluprost) 
0.0015%, latanoprost 0.005%, or travoprost 0.004% on 
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ONH blood flow and on endothelin-1-induced contractions 
in isolated rabbit ciliary artery segments. All therapies 
relaxed the endothelin-1-induced ciliary artery contractions. 
Improvement of the ocular circulation seemed superior 
with tafluprost compared with the other prostaglandin F2α 
analogs.45
Ocular surface and impression cytology samples have 
been compared between tafluprost and other prostaglandin 
analog therapies. Uusitalo et al investigated whether patients 
who exhibit limited tolerability to latanoprost benefited 
from switching to preservative-free prostaglandin tafluprost. 
Throughout the treatment period of 3 months, the drugs 
were equally effective. There was a dramatic decrease in the 
number of patients exhibiting subjective symptoms during 
preservative-free tafluprost treatment (around 50% compared 
to latanoprost at baseline), and a decrease in most of the signs 
of ocular side effects.
The decrease in the number of patients with abnormal 
levels of HLA-DR-positive conjunctival epithelial cells 
and with abnormal levels of MUC5AC-expressing goblet 
cells after preservative-free tafluprost treatment when 
compared to preserved latanoprost at baseline indicates less 
harmful effects on the conjunctiva during treatment with a 
preservative-free prostaglandin solution. Preservative-free 
tafluprost caused less conjunctival hyperemia than the 
latanoprost. Hyperemia with the use of the commercially 
available latanoprost formulation may partly be caused 
by the very high concentration of BAC. Preservative-free 
tafluprost was better tolerated than the commercially 
available formulation of latanoprost in patients who exhib-
ited ocular surface side effects during latanoprost treatment 
at the baseline visit.46
In another study, conjunctival and corneal reactions of 
commercially available latanoprost and preservative-free 
tafluprost were compared in rabbit eyes. The rabbits received 
phosphate buffered saline, preservative-free tafluprost 
0.0015%, latanoprost 0.005%, or BAC 0.02%. All solutions 
were applied at 5-minute intervals for a total of 15 times. 
There were higher expressions of CD45+ and TNFR1+ 
in latanoprost- or BAC-instilled groups compared with 
preservative-free tafluprost and saline groups. Latanoprost 
induced fewer positive cells for inflammatory marker 
expressions in specimens compared with BAC alone, both 
of which were higher than with preservative-free tafluprost 
or saline. Immunohistology showed the same tendency of 
toxic ranking.47
In conclusion, preservative-free tafluprost is a promising 
new prostaglandin agent in the treatment of glaucoma.
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